Pacer Advisors Inc. Buys New Holdings in Roche Holdings AG Basel ADR (OTCMKTS:RHHBY)

Pacer Advisors Inc. bought a new stake in Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 39,796 shares of the company’s stock, valued at approximately $1,397,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Dougherty Wealth Advisers LLC purchased a new stake in shares of Roche Holdings AG Basel during the second quarter worth $45,000. Motco bought a new position in shares of Roche Holdings AG Basel in the second quarter worth $47,000. Advisors Asset Management Inc. bought a new position in shares of Roche Holdings AG Basel in the first quarter worth $144,000. Boston Private Wealth LLC increased its holdings in shares of Roche Holdings AG Basel by 46.6% in the second quarter. Boston Private Wealth LLC now owns 10,240 shares of the company’s stock worth $361,000 after purchasing an additional 3,254 shares during the period. Finally, Hartwell J M Limited Partnership bought a new position in shares of Roche Holdings AG Basel in the second quarter worth $382,000. 0.31% of the stock is owned by hedge funds and other institutional investors.

Several research firms have recently weighed in on RHHBY. UBS Group raised shares of Roche Holdings AG Basel from a “neutral” rating to a “buy” rating in a report on Friday, July 26th. Liberum Capital cut Roche Holdings AG Basel from a “buy” rating to a “hold” rating in a research note on Thursday, June 20th. Zacks Investment Research raised Roche Holdings AG Basel from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research note on Tuesday, July 9th. Deutsche Bank raised Roche Holdings AG Basel from a “hold” rating to a “buy” rating in a research note on Thursday, June 20th. Finally, ValuEngine cut Roche Holdings AG Basel from a “hold” rating to a “sell” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $37.00.

OTCMKTS:RHHBY traded up $0.71 during trading hours on Friday, reaching $34.62. The company had a trading volume of 423,201 shares, compared to its average volume of 816,434. The company has a current ratio of 1.40, a quick ratio of 1.11 and a debt-to-equity ratio of 0.53. Roche Holdings AG Basel ADR has a 52 week low of $28.74 and a 52 week high of $35.90. The firm has a market cap of $237.09 billion, a price-to-earnings ratio of 14.92, a PEG ratio of 2.22 and a beta of 0.48. The firm’s 50 day moving average price is $34.33 and its 200-day moving average price is $33.98.

Roche Holdings AG Basel Profile

Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.

Featured Story: How to calculate the intrinsic value of a stock

Institutional Ownership by Quarter for Roche Holdings AG Basel (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.